ASHAP – an effective salvage therapy for recurrent and refractory malignant lymphomas
暂无分享,去创建一个
N. Kröger | A. Zander | D. Hossfeld | A. Hänel | B. Metzner | W. Krüger | H. Weh | M. Hänel | W. Zeller | M. Hoffknecht | D. Braumann | H. Illiger | D. Hossfeld | F. Fiedler | S. Peters | J. C. Schubert | H. Weh | A. Zander | J. Schubert
[1] F. Cabanillas,et al. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. , 1997, Hematology/oncology clinics of North America.
[2] R. Lifton,et al. Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors , 1997, Bone Marrow Transplantation.
[3] R. Marcus,et al. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients. , 1996, Bone marrow transplantation.
[4] R. Tsang,et al. The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups , 1996, British journal of haematology.
[5] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[6] B. Littenberg,et al. Autologous bone marrrow transplantation versus chemotherapy in relapsed/refractory non‐hodgkin's lymphoma: Estimates of long‐term survival from the recent literatur , 1995 .
[7] W. Velasquez,et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Velasquez,et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] B. Littenberg,et al. Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: estimates of long-term survival from the recent literature. , 1995, American journal of hematology.
[10] S. Tucker,et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Raja,et al. E-SHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] N. Schmitz,et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. A. Tanner,et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Armitage,et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] W. Wilson,et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Strawderman,et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Winfield,et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.
[18] F. Mandelli,et al. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma. , 1993, Haematologica.
[19] B. Coiffier,et al. Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] B. Coiffier,et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Linch,et al. Mini‐BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease , 1992, British journal of haematology.
[22] B. Hillner,et al. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Jaffe,et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] S. Bates,et al. P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.
[25] F. Appelbaum,et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Sutcliffe,et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. , 1990, Bone marrow transplantation.
[27] S. Jagannath,et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.
[28] S. Jagannath,et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. , 1988, Seminars in hematology.
[29] V. Diehl,et al. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. , 1987, Cancer treatment reports.
[30] J. Armitage,et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.
[31] G. Fillet,et al. [Treatment of non-Hodgkin's lymphoma]. , 1987, Revue medicale de Liege.
[32] W. Velasquez,et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Dumont,et al. Autologous bone marrow transplantation in Hodgkin's disease. , 1985, Revue francaise de transfusion et immuno-hematologie.
[34] G. Clamon,et al. Salvage therapy of aggressive non‐Hodgkin's lymphoma with a combination of vinblastine, bleomycin, and cisplatin , 1984, Cancer.
[35] F. Appelbaum,et al. Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Wheeler,et al. Combination chemotherapy of refractory lymphoma with cis‐dichlorodiamineplatinum, vinblastine, and bleomycin , 1982, Cancer.
[37] F. Cabanillas,et al. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. , 1982, Blood.
[38] F. Cavalli,et al. Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B , 1981 .
[39] B. Barlogie,et al. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. , 1981, Cancer research.
[40] F. Cavalli,et al. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. , 1981, Cancer.
[41] C. Coltman,et al. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. , 1979, Cancer treatment reports.
[42] K. Lennert,et al. The Histopathology of Malignant Lymphoma , 1975 .
[43] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[44] R. Peto,et al. Asymptotically efficient rank invariant test procedure (with discussion). , 1972 .
[45] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .